<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>&#43;Inactivated virus on Vishvas&#39;s notes</title>
    <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/inactivated-virus/</link>
    <description>Recent content in &#43;Inactivated virus on Vishvas&#39;s notes</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <atom:link href="https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/inactivated-virus/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Bharat Biotech Covaxin BBV152</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/inactivated-virus/Bharat_Biotech_Covaxin_BBV152/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/inactivated-virus/Bharat_Biotech_Covaxin_BBV152/</guid>
      <description>&lt;ul&gt;&#xA;&lt;li&gt;inactivated / attenuated whole virus particles&lt;/li&gt;&#xA;&lt;li&gt;DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;severe-adverse-reactions&#34;&gt;Severe Adverse reactions&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;1 person developed encephalitis. Was threatened with a lawsuit.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;efficacy&#34;&gt;Efficacy&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;The efficacy against severe COVID-19 disease was 100 per cent (95%CI: 60-100), with an impact on reduction in hospitalisations. The efficacy against asymptomatic COVID-19 infection was 70 per cent, suggesting decreased transmission in COVAXIN recipients.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;dosage-gap&#34;&gt;Dosage gap&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;However, the immunity level produced after the first dose of Covaxin is not as high and &amp;ldquo;this means the second dose should be taken after four weeks to ensure full efficacy&amp;rdquo;.&lt;/li&gt;&#xA;&lt;/ul&gt;</description>
    </item>
    <item>
      <title>Sinopharm vaccine</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/inactivated-virus/Sinopharm_vaccine/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/inactivated-virus/Sinopharm_vaccine/</guid>
      <description>&lt;ul&gt;&#xA;&lt;li&gt;inactivated / attenuated whole virus particles&lt;/li&gt;&#xA;&lt;li&gt;Supposedly 79.34% effective. UAE: 86% effective&lt;/li&gt;&#xA;&lt;/ul&gt;</description>
    </item>
    <item>
      <title>Sinovac CoronaVac</title>
      <link>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/inactivated-virus/Sinovac_CoronaVac/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      <guid>https://vishvAsa.github.io/notes/general_biology/virus/ribo/ortho-rna/corona/wuhan_epidemic/Infection/vaccination/inactivated-virus/Sinovac_CoronaVac/</guid>
      <description>&lt;ul&gt;&#xA;&lt;li&gt;inactivated / attenuated whole virus particles&lt;/li&gt;&#xA;&lt;li&gt;stored in a standard refrigerator at 2-8 degrees Celsius&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;effectiveness&#34;&gt;Effectiveness&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;202107 - No new data has been published on how they fare against variants.&lt;/li&gt;&#xA;&lt;li&gt;The WHO said studies showed the Sinovac vaccine &amp;ldquo;prevented symptomatic disease in 51% of those vaccinated and prevented severe Covid-19 and hospitalization in 100% of the studied population&amp;rdquo; for adults aged 18 and older, when it approved the jab in June.&lt;/li&gt;&#xA;&lt;li&gt;Brazil: 50.38% effective in late-stage trials in Brazil (far below the 78% previously announced)&lt;/li&gt;&#xA;&lt;li&gt;Indonesian drug regulators say interim data from Phase 3 trials showed it is 65.3% effective&lt;/li&gt;&#xA;&lt;/ul&gt;</description>
    </item>
  </channel>
</rss>
